Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
Portfolio Pulse from
Genprex, Inc. announced promising results from a study on NPRL2 gene therapy using their Oncoprex® Delivery System, showing potential as a treatment for anti-PD1 resistant non-small cell lung cancer.
February 13, 2025 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genprex's NPRL2 gene therapy, delivered via the Oncoprex® system, shows potential in treating anti-PD1 resistant non-small cell lung cancer, as per a new study.
The study highlights the potential of Genprex's NPRL2 gene therapy in treating a specific type of lung cancer, which could lead to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100